HER2过度表达乳腺癌的辅助治疗研究进展
被引量：1
摘要
HER2基因与乳腺癌的发生发展及转移有密切关系 ,HER2过度表达与化疗、内分泌治疗抵抗有关 ,进一步的标准化检测及分析方法将对HER2在肿瘤中深入研究起到推动作用。
出处
《临床外科杂志》
2004年第6期370-371,共2页
Journal of Clinical Surgery
参考文献15
-
1Spiridon CI,Ghetie,MA Uhr J,et al.Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo[J].Clinical Cancer Research,2002,8∶1720-1730.
-
2Lobleigh MA,Vogel CL,Tripathy D,et al.Multinational study of the efficacy and safety o humanized anti-HER2monoclonal antibody in women who have HER2-overexpression metastatic breast cancer that has progressed after chemotherapy for metastatic disease[J].J
-
3Wentao Yang,Kristina Klos,Ying Yang,et al.ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A,C, and D in breast carcinoma[J].Cancer,2002,94:2855-2861.
-
4Slamon DJ,Leyland Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J med,2001,344(11):783-792.
-
5Bunone G,Briand PA,Miksicek RJ,et al.Activation of the unliganded estrogen receptor by EGF involves the MAPKinase pathway and direct phosphorylation[J].EMBO J,1996,15:2174-2183.
-
6SJ Houston,TA Plunkett,DM Barnes,et al.Overexpression of c-cerbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer[J].British Journal of Cancer,1999,79:1260-1269.
-
7Lipton A,Ali SM,Leitael K,et al.Elevated serum HER2/neu level predicts decreased response to hormone therapy in metastatic breast cancer[J].Journal of Clinical Oncology,2002,20:1467-1472.
-
8Berry DA,Muss HB,Thor AD,et al.HER2/neu and P53 expression versus tamoxifen resistance in estrogen receptor-positive,node-positive breast cancer[J] Journal of Clinical Ocology,2000,18:3471-3479.
-
9Dowsett M,Harper-Wynne I,Boeddinghaus I,et al.Significant antiproliferative effects of endocrine therapy in ER+HER+breast Carcinomas[J].Eur J cancer,2000,36:S120-S121.
-
10Sylvie Menard,Andrea balsari,Patrizia Casalini,et al.HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviors[J].Clinical Cancer Research,2002,8:520-525.
同被引文献7
-
1赵丽娟,汪静,杨金巧.新辅助化疗对乳腺癌ER、PR、pS2、C-erbB-2、Ki-67表达的影响[J].华西医学,2008,23(5):1006-1008. 被引量：3
-
2刘晓彤,王春涛,秦玲.乳腺癌细针穿刺标本与术后活检组织生物学指标的比较分析[J].武警医学,2006,17(1):67-68. 被引量：1
-
3梁茹 刘旭民.700例针吸细胞学检查诊断分析及体会[J].临床实验与病理学杂志,1988,4(3):153-155.
-
4贾卫娟,周婕,苏逢锡.乳腺癌术前空心针穿刺活检与手术切除标本的免疫组化比较研究[J].岭南现代临床外科,2008,8(6):426-427. 被引量：9
-
5徐月娟,邱少敏.乳腺癌组织中c-erbB-2、ER和PR的表达及与预后的关系[J].山东大学学报（医学版）,2010,48(9):100-103. 被引量：6
-
6王海.乳腺癌穿刺活检组织ER、PR和HER2免疫组化检测准确性的研究[J].医学信息,2011,24(12):3744-3745. 被引量：2
-
7麦国丰,罗荣城,马树东,宋海珠,张军一,季晨阳,郑航,蔡俊杰,丁彦青.HER2表达与乳腺癌预后的相关性研究[J].解放军医学杂志,2003,28(10):902-903. 被引量：17
-
1付秋风,熊勇,孙丽萍,秦贇娜,于晓红.CD44v6和MMP9在子宫内膜癌中表达的研究[J].实用中西医结合临床,2010,10(6):70-72.
-
2费慧娟,余超崙,刘永健,李官成,张慈英,范学军.乳腺癌及乳腺良性肿块雌激素受体检测及分析[J].湖南医学,1990,7(6):321-322. 被引量：1
-
3吴凯,马茂强,王春海,张勇.喉癌发生发展过程中TRAIL和Survivin蛋白的表达研究[J].山东大学耳鼻喉眼学报,2007,21(2):138-140. 被引量：1
-
4郝静,王秀梅,衣翠华,于学军,张昕,扈东艳,李明,于金明.影响乳腺癌雌激素受体表达的临床病理因素分析[J].中国现代普通外科进展,2006,9(4):236-238. 被引量：6
-
5王希泽,宋福林,张雪峰,张忻平,曲化远,宗修锟.3种多药耐药基因在胃癌组织中表达的检测及分析[J].中国实用内科杂志,2003,23(9):532-532.
-
6叶娟,张灏.雌激素受体共调节因子在乳腺癌内分泌治疗抵抗中的作用[J].国际肿瘤学杂志,2012,39(1):31-34.
-
7金琳芳,齐晓薇,陆蕾,浦勇,周心一.非小细胞肺癌中EML4－ALK融合基因的检测及分析[J].国际呼吸杂志,2014,34(16):1203-1206. 被引量：1
-
8宋红群.肺癌患者血清SAPO-1/Fas水平检测及分析[J].临床医药实践,2003,12(5):334-336.
-
9邹洁洁.CA125、CA15-3及CA19-9联检对卵巢癌诊断的价值[J].放射免疫学杂志,2013,26(6):831-832. 被引量：2
-
10周勇安,张志培,田丰,钟代星,杨光,罗立峰,冯征,程少毅,王艳.人Toll样受体4在非小细胞肺癌组织中的表达及意义[J].中国肿瘤临床与康复,2013,20(11):1204-1206.
